David R. Sibley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David R. Sibley has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Mette Skinbjerg
Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA
3 shared publicationsYoon Namkung
Molecular Neuropharmacology Section, NINDS, National Institutes of Health, Bethesda, Maryland 20892-9405, USA
3 shared publicationsChrister Halldin
Psychiatry Section, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
2 shared publicationsConcetta Dipace
2 shared publicationsDavid M. Cabrera
2 shared publications- Jonathan A. Javitch
Department of Molecular Pharmacology and Therapeutics, Columbia University Irving Medical Center, New York, NY
2 shared publications
Latest Publications
- Open Access
- 26 January 2011
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 12 (1) , 27
Activation of the dopamine 1 and dopamine 5 receptors increase skeletal muscle mass and force production under non-atrophying and atrophying conditions
Background: Control of skeletal muscle mass and force production is a complex physiological process involving numerous regulatory systems. Agents that increase skeletal muscle cAMP levels have been shown to modulate skeletal muscle mass and force production. The dopamine 1 receptor and its closely related homolog, the dopamine 5 receptor, are G-protein coupled receptors that are expressed in skeletal muscle and increase cAMP levels when activated. Thus we hypothesize that activation of the dopamine 1 and/or 5 receptor will increase skeletal muscle cAMP levels thereby modulating skeletal muscle mass and force production.Methods: We treated isolated mouse tibialis anterior (TA) and medial gastrocnemius (MG) muscles in tissue bath with the selective dopamine 1 receptor and dopamine 5 receptor agonist SKF 81297 to determine if activation of skeletal muscle dopamine 1 and dopamine 5 receptors will increase cAMP. We dosed wild-type mice, dopamine 1 receptor knockout mice and dopamine 5 receptor knockout mice undergoing casting-induced disuse atrophy with SKF 81297 to determine if activation of the dopamine 1 and dopamine 5 receptors results in hypertrophy of non-atrophying skeletal muscle and preservation of atrophying skeletal muscle mass and force production.Results: In tissue bath, isolated mouse TA and MG muscles responded to SKF 81297 treatment with increased cAMP levels. Treating wild-type mice with SKF 81297 reduced casting-induced TA and MG muscle mass loss in addition to increasing the mass of non-atrophying TA and MG muscles. In dopamine 1 receptor knockout mice, extensor digitorum longus (EDL) and soleus muscle mass and force was not preserved during casting with SKF 81297 treatment, in contrast to significant preservation of casted wild-type mouse EDL and soleus mass and EDL force with SKF 81297 treatment. Dosing dopamine 5 receptor knockout mice with SKF 81297 did not significantly preserve EDL and soleus muscle mass and force although wild-type mouse EDL mass and force was significantly preserved SKF 81297 treatment.Conclusions: These data demonstrate for the first time that treatment with a dopamine 1/5 receptor agonist results in (1) significant preservation of EDL, TA, MG and soleus muscle mass and EDL muscle force production during periods of atrophy and (2) hypertrophy of TA and MG muscle. These effects appear to be mainly mediated by both the dopamine 1 and dopamine 5 receptors.
- 26 January 2011
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 12 (1) , 27
Open AccessActivation of the dopamine 1 and dopamine 5 receptors increase skeletal muscle mass and force production under non-atrophying and atrophying conditions
Background: Control of skeletal muscle mass and force production is a complex physiological process involving numerous regulatory systems. Agents that increase skeletal muscle cAMP levels have been shown to modulate skeletal muscle mass and force production. The dopamine 1 receptor and its closely related homolog, the dopamine 5 receptor, are G-protein coupled receptors that are expressed in skeletal muscle and increase cAMP levels when activated. Thus we hypothesize that activation of the dopamine 1 and/or 5 receptor will increase skeletal muscle cAMP levels thereby modulating skeletal muscle mass and force production.Methods: We treated isolated mouse tibialis anterior (TA) and medial gastrocnemius (MG) muscles in tissue bath with the selective dopamine 1 receptor and dopamine 5 receptor agonist SKF 81297 to determine if activation of skeletal muscle dopamine 1 and dopamine 5 receptors will increase cAMP. We dosed wild-type mice, dopamine 1 receptor knockout mice and dopamine 5 receptor knockout mice undergoing casting-induced disuse atrophy with SKF 81297 to determine if activation of the dopamine 1 and dopamine 5 receptors results in hypertrophy of non-atrophying skeletal muscle and preservation of atrophying skeletal muscle mass and force production.Results: In tissue bath, isolated mouse TA and MG muscles responded to SKF 81297 treatment with increased cAMP levels. Treating wild-type mice with SKF 81297 reduced casting-induced TA and MG muscle mass loss in addition to increasing the mass of non-atrophying TA and MG muscles. In dopamine 1 receptor knockout mice, extensor digitorum longus (EDL) and soleus muscle mass and force was not preserved during casting with SKF 81297 treatment, in contrast to significant preservation of casted wild-type mouse EDL and soleus mass and EDL force with SKF 81297 treatment. Dosing dopamine 5 receptor knockout mice with SKF 81297 did not significantly preserve EDL and soleus muscle mass and force although wild-type mouse EDL mass and force was significantly preserved SKF 81297 treatment.Conclusions: These data demonstrate for the first time that treatment with a dopamine 1/5 receptor agonist results in (1) significant preservation of EDL, TA, MG and soleus muscle mass and EDL muscle force production during periods of atrophy and (2) hypertrophy of TA and MG muscle. These effects appear to be mainly mediated by both the dopamine 1 and dopamine 5 receptors.
- Open Access
- 22 October 2010
- Published by Wiley in Journal of Neurochemistry
- Vol. 115 (6) , 1655-1667
Constitutive phosphorylation by protein kinase C regulates D1dopamine receptor signaling
J. Neurochem.(2010)115,1655–1667. The D1dopamine receptor (D1DAR) is robustly phosphorylated by multiple protein kinases, yet the phosphorylation sites and functional consequences of these modifications are not fully understood. Here, we report that the D1DAR is phosphorylated by protein kinase C (PKC) in the absence of agonist stimulation. Phosphorylation of the D1DAR by PKC is constitutive in nature, can be induced by phorbol ester treatment or through activation of Gq‐mediated signal transduction pathways, and is abolished by PKC inhibitors. We demonstrate that most, but not all, isoforms of PKC are capable of phosphorylating the receptor. To directly assess the functional role of PKC phosphorylation of the D1DAR, a site‐directed mutagenesis approach was used to identify the PKC sites within the receptor. Five serine residues were found to mediate the PKC phosphorylation. Replacement of these residues had no effect on D1DAR expression or agonist‐induced desensitization; however, G protein coupling and cAMP accumulation were significantly enhanced in PKC‐null D1DAR. Thus, constitutive or heterologous PKC phosphorylation of the D1DAR dampens dopamine activation of the receptor, most likely occurring in a context‐specific manner, mediated by the repertoire of PKC isozymes within the cell.
- 22 October 2010
- Published by Wiley in Journal of Neurochemistry
- Vol. 115 (6) , 1655-1667
Open AccessConstitutive phosphorylation by protein kinase C regulates D1dopamine receptor signaling
J. Neurochem.(2010)115,1655–1667. The D1dopamine receptor (D1DAR) is robustly phosphorylated by multiple protein kinases, yet the phosphorylation sites and functional consequences of these modifications are not fully understood. Here, we report that the D1DAR is phosphorylated by protein kinase C (PKC) in the absence of agonist stimulation. Phosphorylation of the D1DAR by PKC is constitutive in nature, can be induced by phorbol ester treatment or through activation of Gq‐mediated signal transduction pathways, and is abolished by PKC inhibitors. We demonstrate that most, but not all, isoforms of PKC are capable of phosphorylating the receptor. To directly assess the functional role of PKC phosphorylation of the D1DAR, a site‐directed mutagenesis approach was used to identify the PKC sites within the receptor. Five serine residues were found to mediate the PKC phosphorylation. Replacement of these residues had no effect on D1DAR expression or agonist‐induced desensitization; however, G protein coupling and cAMP accumulation were significantly enhanced in PKC‐null D1DAR. Thus, constitutive or heterologous PKC phosphorylation of the D1DAR dampens dopamine activation of the receptor, most likely occurring in a context‐specific manner, mediated by the repertoire of PKC isozymes within the cell.
- 1 July 2010
- Published by Elsevier in Molecular Pharmacology
- Vol. 78 (1) , 69-80
Identification of RanBP 9/10 as Interacting Partners for Protein Kinase C (PKC) γ/δ and the D1 Dopamine Receptor: Regulation of PKC-Mediated Receptor Phosphorylation
We reported previously that ethanol treatment regulates D1 receptor phosphorylation and signaling in a protein kinase C (PKC) δ- and PKCγ-dependent fashion by a mechanism that may involve PKC isozyme-specific interacting proteins. Using a PKC isozyme-specific coimmunoprecipitation approach coupled to mass spectrometry, we report the identification of RanBP9 and RanBP10 as novel interacting proteins for both PKCγ and PKCδ. Both RanBP9 and RanBP10 were found to specifically coimmunoprecipitate with both PKCγ and PKCδ; however, this association did not seem to mediate the ethanol regulation of the PKCs. It is noteworthy that the D1 receptor was also found to specifically coimmunoprecipitate with RanBP9/10 from human embryonic kidney (HEK) 293T cells and with endogenous RanBP9 from rat kidney. RanBP9 and RanBP10 were also found to colocalize at the cellular level with the D1 receptor in both kidney and brain tissue. Although overexpression of RanBP9 or RanBP10 in HEK293T cells did not seem to alter the kinase activities of either PKCδ or PKCγ, both RanBP proteins regulated D1 receptor phosphorylation, signaling, and, in the case of RanBP9, expression. Specifically, overexpression of either RanBP9 or RanBP10 enhanced basal D1 receptor phosphorylation, which was associated with attenuation of D1 receptor-stimulated cAMP accumulation. Moreover, treatment of cells with select PKC inhibitors blocked the RanBP9/10-dependent increase in basal receptor phosphorylation, suggesting that phosphorylation of the receptor by PKC is regulated by RanBP9/10. These data support the idea that RanBP9 and RanBP10 may function as signaling integrators and dictate the efficient regulation of D1 receptor signaling by PKCδ and PKCγ.
- 1 July 2010
- Published by Elsevier in Molecular Pharmacology
- Vol. 78 (1) , 69-80
Identification of RanBP 9/10 as Interacting Partners for Protein Kinase C (PKC) γ/δ and the D1 Dopamine Receptor: Regulation of PKC-Mediated Receptor Phosphorylation
We reported previously that ethanol treatment regulates D1 receptor phosphorylation and signaling in a protein kinase C (PKC) δ- and PKCγ-dependent fashion by a mechanism that may involve PKC isozyme-specific interacting proteins. Using a PKC isozyme-specific coimmunoprecipitation approach coupled to mass spectrometry, we report the identification of RanBP9 and RanBP10 as novel interacting proteins for both PKCγ and PKCδ. Both RanBP9 and RanBP10 were found to specifically coimmunoprecipitate with both PKCγ and PKCδ; however, this association did not seem to mediate the ethanol regulation of the PKCs. It is noteworthy that the D1 receptor was also found to specifically coimmunoprecipitate with RanBP9/10 from human embryonic kidney (HEK) 293T cells and with endogenous RanBP9 from rat kidney. RanBP9 and RanBP10 were also found to colocalize at the cellular level with the D1 receptor in both kidney and brain tissue. Although overexpression of RanBP9 or RanBP10 in HEK293T cells did not seem to alter the kinase activities of either PKCδ or PKCγ, both RanBP proteins regulated D1 receptor phosphorylation, signaling, and, in the case of RanBP9, expression. Specifically, overexpression of either RanBP9 or RanBP10 enhanced basal D1 receptor phosphorylation, which was associated with attenuation of D1 receptor-stimulated cAMP accumulation. Moreover, treatment of cells with select PKC inhibitors blocked the RanBP9/10-dependent increase in basal receptor phosphorylation, suggesting that phosphorylation of the receptor by PKC is regulated by RanBP9/10. These data support the idea that RanBP9 and RanBP10 may function as signaling integrators and dictate the efficient regulation of D1 receptor signaling by PKCδ and PKCγ.
- Open Access
- 1 December 2009
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 284 (49) , 34103-34115
G Protein-coupled Receptor Kinase-2 Constitutively Regulates D2 Dopamine Receptor Expression and Signaling Independently of Receptor Phosphorylation
- 1 December 2009
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 284 (49) , 34103-34115
Open AccessG Protein-coupled Receptor Kinase-2 Constitutively Regulates D2 Dopamine Receptor Expression and Signaling Independently of Receptor Phosphorylation
- Open Access
- 1 May 2009
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 284 (22) , 15038-15051
G Protein-coupled Receptor Kinase-mediated Phosphorylation Regulates Post-endocytic Trafficking of the D2 Dopamine Receptor
- 1 May 2009
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 284 (22) , 15038-15051
Open AccessG Protein-coupled Receptor Kinase-mediated Phosphorylation Regulates Post-endocytic Trafficking of the D2 Dopamine Receptor
Pharmacological characterization of 2‐methoxy‐N‐propylnorapomorphine's interactions with D2and D3dopamine receptors
Dopaminergic signaling pathways have been extensively investigated using PET imaging, primarily with antagonist radioligands of D2and D3dopamine receptors (DARs). Recently, agonist radioligands of D2/D3DARs have begun to be developed and employed. One such agonist is (R)‐2‐11CH3O‐N‐n‐propylnorapomorphine (MNPA). Here, we perform a pharmacological characterization of MNPA using recombinant D2and D3DARs expressed in HEK293 cells. MNPA was found to robustly inhibit forskolin‐stimulated cAMP accumulation to the same extent as dopamine in D2or D3DAR‐transfected cells, indicating that it is a full agonist at both receptors. MNPA is ∼50‐fold more potent than dopamine at the D2DAR, but equally potent as dopamine at the D3DAR. MNPA competition binding curves in membrane preparations expressing D2DARs revealed two binding states of high and low‐affinity. In the presence of GTP, only one binding state of low affinity was observed. Direct saturation binding assays using [3H]MNPA revealed similar results as with the competition experiments leading to the conclusion that MNPA binds to the D2DAR in an agonist‐specific fashion. In contrast to membrane preparations, using intact cell binding assays, only one site of low affinity was observed for MNPA and other agonists binding to the D2DAR. MNPA was also found to induce D2DAR internalization to an even greater extent than dopamine as determined using both cell surface receptor binding assays and confocal fluorescence microscopy. Taken together, our data indicate that the PET tracer, MNPA, is a full and potent agonist at both D2and D3receptors. Synapse 63:462–475, 2009.
Pharmacological characterization of 2‐methoxy‐N‐propylnorapomorphine's interactions with D2and D3dopamine receptors
Dopaminergic signaling pathways have been extensively investigated using PET imaging, primarily with antagonist radioligands of D2and D3dopamine receptors (DARs). Recently, agonist radioligands of D2/D3DARs have begun to be developed and employed. One such agonist is (R)‐2‐11CH3O‐N‐n‐propylnorapomorphine (MNPA). Here, we perform a pharmacological characterization of MNPA using recombinant D2and D3DARs expressed in HEK293 cells. MNPA was found to robustly inhibit forskolin‐stimulated cAMP accumulation to the same extent as dopamine in D2or D3DAR‐transfected cells, indicating that it is a full agonist at both receptors. MNPA is ∼50‐fold more potent than dopamine at the D2DAR, but equally potent as dopamine at the D3DAR. MNPA competition binding curves in membrane preparations expressing D2DARs revealed two binding states of high and low‐affinity. In the presence of GTP, only one binding state of low affinity was observed. Direct saturation binding assays using [3H]MNPA revealed similar results as with the competition experiments leading to the conclusion that MNPA binds to the D2DAR in an agonist‐specific fashion. In contrast to membrane preparations, using intact cell binding assays, only one site of low affinity was observed for MNPA and other agonists binding to the D2DAR. MNPA was also found to induce D2DAR internalization to an even greater extent than dopamine as determined using both cell surface receptor binding assays and confocal fluorescence microscopy. Taken together, our data indicate that the PET tracer, MNPA, is a full and potent agonist at both D2and D3receptors. Synapse 63:462–475, 2009.
- Open Access
- 1 December 2008
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 283 (52) , 36441-36453
Reciprocal Modulation of Function between the D1 and D2 Dopamine Receptors and the Na+,K+-ATPase
- 1 December 2008
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 283 (52) , 36441-36453
Open AccessReciprocal Modulation of Function between the D1 and D2 Dopamine Receptors and the Na+,K+-ATPase
- Open Access
- 1 February 2004
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 279 (9) , 7999-8010
The Role of Phosphorylation in D1 Dopamine Receptor Desensitization
- 1 February 2004
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 279 (9) , 7999-8010
Open AccessThe Role of Phosphorylation in D1 Dopamine Receptor Desensitization